TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma

References

• Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG, Jr, Livingston DM, Orkin SH, Greenberg ME. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85(4):549-61; PMID:8653790; http://dx.doi.org/10.1016/S0092-8674(00)81255-6
   PubMed Web of Science ®Google Scholar
• Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85(4):537-48; PMID:8653789; http://dx.doi.org/10.1016/S0092-8674(00)81254-4
   PubMed Web of Science ®Google Scholar
• Oswald F, Dobner T, Lipp M. The E2F transcription factor activates a replication-dependent human H2A gene in early S phase of the cell cycle. Mol Cell Biol 1996; 16(5):1889-95; PMID:8628255; http://dx.doi.org/10.1128/MCB.16.5.1889
   PubMed Web of Science ®Google Scholar
• Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, Fan J, Gorlick R, Goker E, Bertino JR. Molecular mechanisms of resistance to antifolates, a review. Acta Biochimica Polonica 1995; 42(4):457-64; PMID:8852336
   PubMed Web of Science ®Google Scholar
• Kirch HC, Putzer B, Schwabe G, Gnauck HK, Schulte Holthausen H. Regulation of adenovirus 12 E1A transcription: E2F and ATF motifs in the E1A promoter bind nuclear protein complexes including E2F1, DP-1, cyclin A and/or RB and mediate transcriptional (auto)activation. Cell Mol Biol Res 1993; 39(8):705-16; PMID:7951410
   PubMedGoogle Scholar
• Gatzka M, Walsh CM. Apoptotic signal transduction and T cell tolerance. Auto Immunity 2007; 40(6):442-52
   PubMed Web of Science ®Google Scholar
• Ramos SJ, Hernandez JB, Gatzka M, Walsh CM. Enhanced T cell apoptosis within Drak2-deficient mice promotes resistance to autoimmunity. J Immunol 2008; 181(11):7606-16; PMID:19017949; http://dx.doi.org/10.4049/jimmunol.181.11.7606
   PubMed Web of Science ®Google Scholar
• Carreno LJ, Gonzalez PA, Kalergis AM. Modulation of T cell function by TCR/pMHC binding kinetics. Immuno Biol 2006; 211(1-2):47-64; http://dx.doi.org/10.1016/j.imbio.2005.09.003
   PubMed Web of Science ®Google Scholar
• Zhao H, Jin S, Fan F, Fan W, Tong T, Zhan Q. Activation of the transcription factor Oct-1 in response to DNA damage. Cancer Res 2000; 60(22):6276-80; PMID:11103783
   PubMed Web of Science ®Google Scholar
• Hafezi F, Marti A, Grimm C, Wenzel A, Reme CE. Differential DNA binding activities of the transcription factors AP-1 and Oct-1 during light-induced apoptosis of photoreceptors. Vision Res 1999; 39(15):2511-8; PMID:10396620; http://dx.doi.org/10.1016/S0042-6989(98)00313-7
   PubMed Web of Science ®Google Scholar
• Szekeres K, Koul R, Mauro J, Lloyd M, Johnson J, Blanck G. An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment. Exp Mol Pathol 2014; 97(3):585-9; PMID:25236570; http://dx.doi.org/10.1016/j.yexmp.2014.09.010
   PubMed Web of Science ®Google Scholar
• Sikora E, Grassilli E, Radziszewska E, Bellesia E, Barbieri D, Franceschi C. Transcription factors DNA-binding activity in rat thymocytes undergoing apoptosis after heat-shock or dexamethasone treatment. Biochem Biophys Res Commun 1993; 197(2):709-15; PMID:8267607; http://dx.doi.org/10.1006/bbrc.1993.2537
   PubMed Web of Science ®Google Scholar
• Berry DE, Lu Y, Schmidt B, Fallon PG, O'Connell C, Hu SX, Xu HJ, Blanck G. Retinoblastoma protein inhibits IFN-gamma induced apoptosis. Oncogene 1996; 12(8):1809-19; PMID:8622902
   PubMed Web of Science ®Google Scholar
• Zheng L, Roeder RG, Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 2003; 114(2):255-66; PMID:12887926; http://dx.doi.org/10.1016/S0092-8674(03)00552-X
   PubMed Web of Science ®Google Scholar
• La Bella F, Heintz N. Histone gene transcription factor binding in extracts of normal human cells. Mol Cell Biol 1991; 11(12):5825-31; PMID:1944265; http://dx.doi.org/10.1128/MCB.11.12.5825
   PubMed Web of Science ®Google Scholar
• Hirsch B, Hummel M, Bentink S, Fouladi F, Spang R, Zollinger R, Stein H, Durkop H. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008; 172(2):510-20; PMID:18187570; http://dx.doi.org/10.2353/ajpath.2008.070858
   PubMed Web of Science ®Google Scholar
• Nishikori M, Ohno H, Haga H, Uchiyama T. Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci 2005; 96(8):487-97; PMID:16108830; http://dx.doi.org/10.1111/j.1349-7006.2005.00078.x
   PubMed Web of Science ®Google Scholar
• Lu H, Hallstrom TC. The nuclear protein UHRF2 is a direct target of the transcription factor E2F1 in the induction of apoptosis. J Biol Chem 2013; 288(33):23833-43; PMID:23833190; http://dx.doi.org/10.1074/jbc.M112.447276
   PubMed Web of Science ®Google Scholar
• Lu H, Liang X, Issaenko OA, Hallstrom TC. Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets. Cell Cycle 2011; 10(19):3317-26; PMID:21937878; http://dx.doi.org/10.4161/cc.10.19.17618
   PubMed Web of Science ®Google Scholar
• McKay BC, Stubbert LJ, Fowler CC, Smith JM, Cardamore RA, Spronck JC. Regulation of ultraviolet light-induced gene expression by gene size. Proc Natl Acad Sci U S A 2004; 101(17):6582-6; PMID:15087501; http://dx.doi.org/10.1073/pnas.0308181101
   PubMed Web of Science ®Google Scholar
• Mauro JA, Blanck G. Functionally distinct gene classes as bigger or smaller transcription factor traps: a possible stochastic component to sequential gene expression programs in cancer. Gene 2014; 536(2):398-406; PMID:24291030; http://dx.doi.org/10.1016/j.gene.2013.11.013
   PubMed Web of Science ®Google Scholar
• Mauro JA, Butler SN, Ramsamooj M, Blanck G. Copy number loss or silencing of apoptosis-effector genes in cancer. Gene 2015; 554(1):50-7; PMID:25307873; http://dx.doi.org/10.1016/j.gene.2014.10.021
   PubMed Web of Science ®Google Scholar
• Teitz T, Wei T, Liu D, Valentine V, Valentine M, Grenet J, Lahti JM, Kidd VJ. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene 2002; 21(12):1848-58; PMID:11896617; http://dx.doi.org/10.1038/sj.onc.1205180
   PubMed Web of Science ®Google Scholar
• Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6(5):529-35; PMID:10802708; http://dx.doi.org/10.1038/75007
   PubMed Web of Science ®Google Scholar
• Peirce SK, Findley HW. High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity. Oncology Reports 2009; 22(6):1443-9; PMID:19885598; http://dx.doi.org/10.3892/or_00000586
   PubMed Web of Science ®Google Scholar
• Fulda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999; 18(7):1479-86; PMID:10050884; http://dx.doi.org/10.1038/sj.onc.1202435
   PubMed Web of Science ®Google Scholar
• Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harbor Perspectives Med 2013; 3(10):a014415; ; http://dx.doi.org/10.1101/cshperspect.a014415
   PubMed Web of Science ®Google Scholar
• Frangione ML, Lockhart JH, Morton DT, Pava LM, Blanck G. Anticipating designer drug-resistant cancer cells. Drug Discov Today 2015; 20(7):790-3; PMID:25697478; http://dx.doi.org/10.1016/j.drudis.2015.02.005
   PubMed Web of Science ®Google Scholar
• Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 2014; 87(3):381-9; PMID:24291778; http://dx.doi.org/10.1016/j.bcp.2013.11.013
   PubMed Web of Science ®Google Scholar
• Garcia M, Mauro JA, Ramsamooj M, Blanck G. Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs. Cell Cycle 2015; 14(15):2494-500; PMID:25945879; http://dx.doi.org/10.1080/15384101.2015.1044179
   PubMed Web of Science ®Google Scholar
• Parry ML, Ramsamooj M, Blanck G. Big genes are big mutagen targets: A connection to cancerous, spherical cells? Cancer Letters 2015; 356(2 Pt B):479-82
   PubMed Web of Science ®Google Scholar
• Stoll BA. Hypothesis: breast cancer regression under oestrogen therapy. British Medical J 1973; 3(5877):446-50; http://dx.doi.org/10.1136/bmj.3.5877.446
   PubMed Web of Science ®Google Scholar
• Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR, Giovanella BC. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 1993; 53(7):1577-82; PMID:8453626
   PubMed Web of Science ®Google Scholar
• Kessel D. Modes of resistance to antitumor agents. Vivo 1994; 8(5):829-34; PMID:7727732
   PubMedGoogle Scholar
• Fawcett TJ, Parry ML, Blanck G. A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. Cancer Genomics Proteomics 2015; 12(6):283-90; PMID:26543077
   PubMed Web of Science ®Google Scholar
• Long K, Abuelenen T, Pava L, Bastille M, Blanck G. Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes. Genes Cancer 2011; 2(10):927-31; PMID:22701759
   PubMedGoogle Scholar